T1000	Negation 342 344	To
E1000	Negation:T1000 Scope:T1001
T1001	Span 342 405	To study whether this represents glucocorticoid (GC) resistance
T1002	Negation 312 315	not
E1001	Negation:T1002 Scope:T1003
T1003	Span 312 340	not have Cushingoid features
T1004	Negation 583 585	No
E1002	Negation:T1004 Scope:T1005
T1005	Span 583 639	No receptor abnormalities were detected in the MDD group
T1006	Speculation 351 358	whether
E1003	Speculation:T1006 Scope:T1007
T1007	Span 351 451	whether this represents glucocorticoid (GC) resistance, [3H]-DEX-binding assays were used to measure
T1008	Speculation 741 749	probably
E1004	Speculation:T1008 Scope:T1009
T1009	Span 741 790	probably lies beyond the initial receptor binding
T1010	Negation 679 683	lack
E1005	Negation:T1010 Scope:T1011
T1011	Span 679 727	lack of responsiveness to GC in the MDD patients
T1012	Negation 1101 1104	not
E1006	Negation:T1012 Scope:T1013
T1013	Span 1101 1247	not correlate significantly with the degree of receptor down-regulation, severity of depression or cortisol concentrations across all the subjects
T1014	Negation 1034 1037	not
E1007	Negation:T1014 Scope:T1015
T1015	Span 1034 1060	not in the depressed group
T1016	Speculation 1303 1313	suggesting
E1008	Speculation:T1016 Scope:T1017
T1017	Span 1303 1386	suggesting that GC resistance in MDD results from a GC receptor-binding abnormality
T1018	Negation 1266 1269	not
E1009	Negation:T1018 Scope:T1019
T1019	Span 1266 1386	not lend support to previous reports suggesting that GC resistance in MDD results from a GC receptor-binding abnormality
